News | July 28, 2021
Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
The company is confident of commencing production at both Mahad and Chiplun units soon
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
Sun Pharma has committed Rs. 100 crores towards these initiatives
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
Subscribe To Our Newsletter & Stay Updated
